HHS acknowledged in a statement on Operation Trailblazer that "a growing share of early-stage clinical research has moved ...

In a landmark decision for people with early type 1 diabetes (T1D) in the UK, Sanofi's first-of-its-kind therapy Tzield, ...

With the third trial in the programme, Boehringer has set its sights on positioning Hernexeos as adjuvant monotherapy – ...

One of the antibody-drug conjugates at the heart of Pfizer's $43 billion acquisition of Seagen three years ago has failed a keenly anticipated phase 3 trial in lung cancer. The results of the ...

CARSgen Therapeutics has claimed approval in China, its home market, for satricabtagene autoleucel (satri-cel), said to be ...

Genpact and analyst firm HFS Research have published a new global study, ‘The $18 Trillion Opportunity: How Four Enterprise ...

Details are starting to emerge of last week's cyberattack on Novo Nordisk, which now appears to have been a $25 million ...

Paulo Fontoura, currently chief medical officer of Xaira Therapeutics, will replace Houman Ashrafian as Sanofi's R&D head on 1st September. The R&D baton at Sanofi will soon be handed over, as the ...

In the first piece of news from the BIO conference that gets underway in San Diego today, Insilico Medicine has teamed up ...

AbbVie has announced its biggest acquisition since the $63 billion mega-merger with Allergan in 2020, agreeing to take control of immunology specialist Apogee Therapeutics in a $10.9 billion deal. The ...

The first generic alternative to Roche's oral drug for influenza, Xofluza, has been approved by the FDA and should be ...

The FDA refused to accept uniQure's filing for AMT-130 last November, and earlier this year the Dutch biotech said it had ...